 MALVERN, Pa., Jan. 21, 2021 GLOBE NEWSWIRE -- Baudax Bio, Inc. Nasdaq: BXRX, a pharmaceutical company focused on therapeutics for acute care settings, today announced the agreement by an accredited healthcare-focused institutional investor to cash exercise certain warrants to purchase up to an aggregate of 10,300,430 shares of common stock having an exercise price of 1.18 issued by the company in December 2020. The shares of common stock issuable upon exercise of the warrants are registered pursuant to a registration statement on Form S-3 File No. 333-243488. In consideration for the immediate exercise of the warrants for cash, the company will sell to the exercising holder an additional warrant pursuant to the registration statement. The new warrant will be cash exercisable for an aggregate of up to 10,300,430 shares of common stock at an exercise price of 1.60 per share and have a term of exercise equal to five years. The purchase price of the additional warrant will be 1,287,553.75, or 0.125 per warrant share. 